* Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment * Multiple myeloma, a malignant plasma cell disorder, continues to challenge the medical community with its complex pathophysiology and resistance to conventional therapies. However, recent advancements in CD38-directed therapies are transforming the landscape of multiple myeloma treatment, offering new hope for patients and reshaping the multiple myeloma market. For More https://www.delveinsight.com/blog/cd38-directed-therapies-for-multiple-myeloma-treatment